Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.

Abstract excerpt

Here, we report a case of a 36-year-old female patient with metastatic non-small cell lung cancer (NSCLC) harboring EGFR-ANXA2 and EGFR-RAD51 double fusion mutations with BRCA2 (nonsense mutation of exon 11) and ATR mutations (Exon 44 variable shear mutation) identified by next generation sequencing (NGS). The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Annexin A2